SAB Biotherapeutics (SABS) Net Margin (2021 - 2024)
SAB Biotherapeutics (SABS) posted Net Margin of 9934.52% for Q4 2024, down 256.37% on a QoQ basis from 2787.69% in Q2 2024, and down 244077.0% year-over-year from N/an in Q1 2024.
SAB Biotherapeutics (SABS) Net Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 9934.52% for Q4 2024.
- Quarterly Net Margin fell 244077.0% year-over-year to 9934.52% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2579.03% (down 69453.0% YoY) and the FY2024 annual result came in at 2579.03%, down 69453.0% from the prior year.
- Net Margin was 9934.52% for Q4 2024 at SAB Biotherapeutics, down from 2787.69% in the prior quarter.
- Across five years, Net Margin topped out at 8.35% in Q1 2022 and bottomed at 9934.52% in Q4 2024.
- A 4-year average of 2082.04% and a median of 364.42% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin slumped 797092 bps — and 2024, when it surged 525843 bps.
- SAB Biotherapeutics' Net Margin stood at 104.46% in 2021, then tumbled by 249 bps to 364.42% in 2022, then tumbled by 1956 bps to 7493.75% in 2023, then sank by 33 bps to 9934.52% in 2024.
- Business Quant data shows SABS's Net Margin at 9934.52% in Q4 2024, 2787.69% in Q2 2024, and 532.06% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -9,934.52% |
| Jun 30, 2024 | -2,787.69% |
| Mar 31, 2024 | -532.06% |
| Dec 31, 2023 | -7,493.75% |
| Sep 30, 2023 | -402.59% |
| Jun 30, 2023 | -8,046.13% |
| Mar 31, 2023 | -1,265.50% |
| Dec 31, 2022 | -364.42% |
| Sep 30, 2022 | -197.12% |
| Jun 30, 2022 | -75.21% |
| Mar 31, 2022 | 8.35% |
| Dec 31, 2021 | -104.46% |
| Sep 30, 2021 | -27.66% |
| Jun 30, 2021 | -16.15% |
| Mar 31, 2021 | 8.33% |